GABBR1

GABBR1 encodes the ligand-binding subunit of the obligatory GABAB heterodimeric G protein-coupled receptor, which requires heterodimerization with GABBR2 for surface expression and function. The GABBR1 subunit harbors the orthosteric GABA-binding site in its Venus flytrap domain, and de novo missense variants at or near this site reduce GABA potency and efficacy, while transmembrane-domain variants can abolish receptor activity by preventing cell-surface trafficking; additional variants produce gain-of-function constitutive activity, demonstrating a bidirectional spectrum of pathogenic mechanisms (PMID:36103875, PMID:41803176). Beyond its canonical role in neuronal inhibition and control of sympathetic tone—where its expression is regulated post-transcriptionally by miR-7b downstream of an angiotensin II/AT1R/HoxD10 pathway in the paraventricular nucleus (PMID:26699387)—GABBR1 is required for hematopoietic stem and progenitor cell proliferation, self-renewal, and B-cell differentiation, as demonstrated by reduced bone-marrow HSPC numbers and competitive reconstitution failure in Gabbr1-knockout mice (PMID:32881992). GABBR1 expression is also regulated by miR-17/20/106 family members via direct 3′-UTR binding, and its downregulation promotes colorectal cancer cell proliferation and invasion, consistent with a tumor-suppressive role in that context (PMID:27230463).

1. 2001 Medium

   Cloning of murine Gabbr1 established the gene's conserved structure, CNS-predominant expression, and alternative splicing pattern shared with the human orthologue, providing the molecular framework for subsequent functional studies.

   Evidence cDNA cloning, tissue distribution analysis, and radiation hybrid mapping in mouse

   PMID:11306808

   Open questions at the time

   • No functional assay performed—expression pattern only
   • Protein-level validation of splice variants not demonstrated
2. 2015 High

   Identification of a complete ANG II/AT1R/HoxD10/miR-7b pathway that post-transcriptionally silences GABBR1 in the hypothalamic PVN revealed how GABBR1 levels are dynamically regulated to modulate sympathetic outflow in heart failure.

   Evidence Luciferase reporter with 3′-UTR mutagenesis, miR-7b antisense PVN infusion, AT1R knockdown, and coronary-artery-ligation CHF rat model

   PMID:26699387

   Open questions at the time

   • Whether this pathway operates in PVN neurons of species other than rat is untested
   • Direct electrophysiological consequences of miR-7b-mediated GABBR1 reduction in PVN neurons not measured
3. 2016 Medium

   Demonstration that miR-17/20/106 family members directly target the GABBR1 3′-UTR to suppress its expression broadened the post-transcriptional regulatory landscape of GABBR1 and implicated its loss in colorectal cancer proliferation and invasion.

   Evidence Luciferase reporter assay, forced expression/knockdown rescue in HCT116 and HT-29 cells, proliferation and invasion assays

   PMID:27230463

   Open questions at the time

   • Tumor-suppressive role of GABBR1 demonstrated only in cell lines, not validated in patient-derived models or in vivo
   • Downstream signaling pathway by which GABBR1 suppresses proliferation/invasion not identified
4. 2021 High

   Gabbr1 knockout mice revealed a non-neuronal role for GABBR1 in hematopoietic stem cell self-renewal, proliferation, and B-cell differentiation, establishing the bone marrow niche as a GABA-responsive compartment.

   Evidence Constitutive Gabbr1 KO mice, competitive transplantation, colony-forming assays, imaging mass spectrometry of GABA in bone marrow, ex vivo agonist treatment of human cord blood HSPCs followed by xenograft

   PMID:32881992

   Open questions at the time

   • Cell-intrinsic versus niche-mediated contributions not fully dissected
   • Downstream G-protein signaling cascade mediating HSPC self-renewal not characterized
5. 2022 High

   Functional characterization of de novo GABBR1 missense variants established that the orthosteric binding site and transmembrane domains are critical determinants of receptor activity and surface trafficking, linking GABBR1 variants to a neurodevelopmental disorder.

   Evidence In vitro GABA dose-response curves, cell-surface expression assays, and active-site mutagenesis in transfected HEK293 cells

   PMID:36103875

   Open questions at the time

   • Structural basis for how each variant disrupts function not resolved at atomic level
   • Patient phenotype–genotype correlation limited by small cohort size
6. 2026 High

   Expanded variant characterization demonstrated that GABBR1 pathogenic variants produce both gain- and loss-of-function effects—including increased constitutive activity—establishing a bidirectional disease mechanism that cannot be predicted computationally.

   Evidence In vitro pharmacological receptor assays and surface expression measurements for multiple novel variants

   PMID:41803176

   Open questions at the time

   • Whether gain-of-function variants respond differently to baclofen or other GABAB modulators is untested
   • In vivo neurophysiological consequences of constitutively active variants not modeled

• The structural basis of GABBR1-GABBR2 heterodimer assembly, the full downstream signaling cascade in non-neuronal tissues (bone marrow, liver), and variant-specific therapeutic strategies remain unresolved.
• No high-resolution structure of disease-associated GABBR1 variant heterodimers
• Signaling intermediates between GABBR1 activation and HSPC self-renewal unknown
• Pharmacological rescue strategies for trafficking-deficient variants not explored